182 related articles for article (PubMed ID: 34487985)
21. Olaparib (LYNPARZAO) Ovarian cancer: spare patients who are in remission.
Prescrire Int; 2017 Jan; 26(178):9-12. PubMed ID: 30730634
[TBL] [Abstract][Full Text] [Related]
22. Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
Eakin CM; Norton TJ; Monk BJ; Chase DM
Gynecol Oncol; 2020 Nov; 159(2):581-587. PubMed ID: 32972786
[TBL] [Abstract][Full Text] [Related]
23. Safety of PARP inhibitors as maintenance therapy in ovarian cancer.
Cecere SC; Casartelli C; Forte M; Pignata S; Pisano C
Expert Opin Drug Saf; 2023; 22(10):897-908. PubMed ID: 37668154
[TBL] [Abstract][Full Text] [Related]
24. Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
Au WY; Chan LC; Liang R; Kwong YL
Am J Hematol; 2006 Jun; 81(6):471-3. PubMed ID: 16680740
[No Abstract] [Full Text] [Related]
25. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M; Coleman RL; Westin SN
Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
[TBL] [Abstract][Full Text] [Related]
26. Second cancers in chronic lymphocytic leukemia: growing importance in the era of improved treatment outcomes.
Langerbeins P; Maurer C; Cramer P; Eichhorst B; Hallek M
Leuk Lymphoma; 2015 Jun; 56(6):1575-6. PubMed ID: 25804766
[No Abstract] [Full Text] [Related]
27. Acute myeloid leukemia as an adverse event in a patient treated with a poly(ADP-ribose) polymerase (PARP) inhibitor.
Girard S; Lours C
Am J Hematol; 2023 Oct; 98(10):1665-1666. PubMed ID: 37226864
[No Abstract] [Full Text] [Related]
28. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
29. Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Response.
Marmouset V; Morice PM; Pagès A; Leary A; Micol JB
Clin Cancer Res; 2023 Mar; 29(6):1158-1159. PubMed ID: 36916192
[No Abstract] [Full Text] [Related]
30. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Markman M
Womens Health (Lond); 2018; 14():1745505717750694. PubMed ID: 29313444
[TBL] [Abstract][Full Text] [Related]
31. Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review.
Borrelli EP; McGladrigan CG
J Oncol Pharm Pract; 2020 Dec; 26(8):1977-1986. PubMed ID: 32659172
[TBL] [Abstract][Full Text] [Related]
32. Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.
Niparuck P; Kanoksil W; Chuncharunee S; Boonsakan P; Ungkanont A; Angchaisuksiri P; Karntisaviwat K; Apilugsanachit A; Rerkamnuatchoke B; Jootar S; Nitiyanant P; Atichartakarn V
Leuk Lymphoma; 2010 Nov; 51(11):2120-5. PubMed ID: 20846095
[No Abstract] [Full Text] [Related]
33. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
[TBL] [Abstract][Full Text] [Related]
34. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
35. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
[TBL] [Abstract][Full Text] [Related]
36. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
37. Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Letter.
Batalini F; Mina LA; Mina A
Clin Cancer Res; 2023 Mar; 29(6):1157. PubMed ID: 36916193
[No Abstract] [Full Text] [Related]
38. Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: A single-center experience.
Todisco E; Gigli F; Mantiero M; Sammassimo S; Pastano R; Ronchini C; Parma G; Lapresa MT; Iori AP; Bertolini F; Corsini C; Gregato G; Poletti C; Colombo N; Tarella C
Int J Cancer; 2021 Jan; 148(1):170-177. PubMed ID: 32856727
[TBL] [Abstract][Full Text] [Related]
39. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes.
Ballen KK; Antin JH
Hematol Oncol Clin North Am; 1993 Apr; 7(2):477-93. PubMed ID: 8468276
[TBL] [Abstract][Full Text] [Related]
40. Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
Havrilesky LJ; Lim S; Ehrisman JA; Lorenzo A; Alvarez Secord A; Yang JC; Johnson FR; Gonzalez JM; Reed SD
Gynecol Oncol; 2020 Mar; 156(3):561-567. PubMed ID: 31982178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
